Estimation of the risk of secondary malignancy arising from whole-breast irradiation

Comparison of five radiotherapy modalities, including TomoHDA

Eun Young Han, Nava Paudel, Jiwon Sung, Myonggeun Yoon, Weon Kuu Chung, Dong Wook Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy.

Original languageEnglish
Pages (from-to)22960-22969
Number of pages10
JournalOncotarget
Volume7
Issue number16
DOIs
Publication statusPublished - 2016 Apr 19

Fingerprint

Breast
Radiotherapy
Radiation
Neoplasms
Breast Neoplasms
Therapeutics
Intensity-Modulated Radiotherapy
Second Primary Neoplasms
Life Expectancy
Radio
Glass
Survivors
Pneumonia

Keywords

  • Breast
  • IMRT
  • Secondary malignancy
  • TomoHDA
  • VMAT

ASJC Scopus subject areas

  • Oncology

Cite this

Estimation of the risk of secondary malignancy arising from whole-breast irradiation : Comparison of five radiotherapy modalities, including TomoHDA. / Han, Eun Young; Paudel, Nava; Sung, Jiwon; Yoon, Myonggeun; Chung, Weon Kuu; Kim, Dong Wook.

In: Oncotarget, Vol. 7, No. 16, 19.04.2016, p. 22960-22969.

Research output: Contribution to journalArticle

Han, Eun Young ; Paudel, Nava ; Sung, Jiwon ; Yoon, Myonggeun ; Chung, Weon Kuu ; Kim, Dong Wook. / Estimation of the risk of secondary malignancy arising from whole-breast irradiation : Comparison of five radiotherapy modalities, including TomoHDA. In: Oncotarget. 2016 ; Vol. 7, No. 16. pp. 22960-22969.
@article{34c0fcfd027d478892723be02a1bf0af,
title = "Estimation of the risk of secondary malignancy arising from whole-breast irradiation: Comparison of five radiotherapy modalities, including TomoHDA",
abstract = "The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy.",
keywords = "Breast, IMRT, Secondary malignancy, TomoHDA, VMAT",
author = "Han, {Eun Young} and Nava Paudel and Jiwon Sung and Myonggeun Yoon and Chung, {Weon Kuu} and Kim, {Dong Wook}",
year = "2016",
month = "4",
day = "19",
doi = "10.18632/oncotarget.8392",
language = "English",
volume = "7",
pages = "22960--22969",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Estimation of the risk of secondary malignancy arising from whole-breast irradiation

T2 - Comparison of five radiotherapy modalities, including TomoHDA

AU - Han, Eun Young

AU - Paudel, Nava

AU - Sung, Jiwon

AU - Yoon, Myonggeun

AU - Chung, Weon Kuu

AU - Kim, Dong Wook

PY - 2016/4/19

Y1 - 2016/4/19

N2 - The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy.

AB - The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy.

KW - Breast

KW - IMRT

KW - Secondary malignancy

KW - TomoHDA

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84965080980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965080980&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8392

DO - 10.18632/oncotarget.8392

M3 - Article

VL - 7

SP - 22960

EP - 22969

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -